SEK138.50
0.22% yesterday
Stockholm, Aug 25, 05:30 pm CET
ISIN
SE0011205202
Symbol
VITR

Vitrolife Stock price

SEK138.50
-9.60 6.48% 1M
-57.50 29.34% 6M
-76.50 35.58% YTD
-82.90 37.44% 1Y
-133.90 49.16% 3Y
-88.50 38.99% 5Y
+105.50 319.70% 10Y
+133.82 2,859.40% 20Y
Stockholm, Closing price Mon, Aug 25 2025
-0.30 0.22%
ISIN
SE0011205202
Symbol
VITR
Industry

Key metrics

Basic
Market capitalization
SEK18.4b
Enterprise Value
SEK19.5b
Net debt
SEK1.1b
Cash
SEK921.0m
Shares outstanding
135.4m
Valuation (TTM | estimate)
P/E
41.3 | 40.0
P/S
5.2 | 5.1
EV/Sales
5.5 | 5.4
EV/FCF
45.4
P/B
1.4
Dividends
DPS
SEK1.10
Yield 1Y | 5Y
0.8% | 0.4%
Growth 1Y | 5Y
10.0% | -
Payout 1Y | 3Y
29.0% | -13.6%
Increased
3 Years
Financials (TTM | estimate)
Revenue
SEK3.5b | SEK3.6b
EBITDA
SEK946.0m | SEK1.3b
EBIT
SEK687.0m | SEK814.5m
Net Income
SEK455.0m | SEK470.3m
Free Cash Flow
SEK429.0m
Growth (TTM | estimate)
Revenue
0.1% | -0.1%
EBITDA
128.1% | 18.8%
EBIT
119.3% | 2.8%
Net Income
112.0% | -8.3%
Free Cash Flow
-36.6%
Margin (TTM | estimate)
Gross
58.8%
EBITDA
26.7% | 34.8%
EBIT
19.4%
Net
12.9% | 13.0%
Free Cash Flow
12.1%
Financial Health
Equity Ratio
78.2%
Return on Equity
3.8%
ROCE
4.2%
ROIC
3.3%
Debt/Equity
0.2
More
EPS
SEK3.4
FCF per Share
SEK3.2
Short interest
-
Employees
1k
Rev per Employee
SEK3.1m
Show more

Is Vitrolife a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Vitrolife Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Vitrolife forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Vitrolife forecast:

Buy
82%
Hold
18%

Financial data from Vitrolife

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,539 3,539
0% 0%
100%
- Direct Costs 1,457 1,457
3% 3%
41%
2,082 2,082
2% 2%
59%
- Selling and Administrative Expenses 1,009 1,009
2% 2%
29%
- Research and Development Expense 108 108
8% 8%
3%
946 946
128% 128%
27%
- Depreciation and Amortization 259 259
37% 37%
7%
EBIT (Operating Income) EBIT 687 687
119% 119%
19%
Net Profit 455 455
112% 112%
13%

In millions SEK.

Don't miss a Thing! We will send you all news about Vitrolife directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. Its products and services include oocyte retrieval needles, sperm processing, IVF media and oil, micromanipulation pipettes, labware, benchtop incubators, time-lapse systems, preimplantation genetic testing, cryopreservation, laser and imaging systems, and lab quality control systems. The firm operates through the following geographical segments: Europe, Middle East, and Africa (EMEA); North and South America; Japan and Pacific; and Asia. The company was founded in 1994 and is headquartered in Gothenburg, Sweden.

Head office Sweden
CEO Bronwyn O'Connor
Employees 1,150
Founded 1989
Website www.vitrolife.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today